Skip to main content
← U-M RESEARCH COMPLIANCE PROGRAMS ← Research A-Z Gateway ← Medical School Office of Research Homepage
University of Michigan Medical School Logo Medical School Office of Research A-Z Logo Logo
Research A to Z
  • Menu
  • Templates
  • SOPs
  • Guidance
  • Policies
  • Informational
  • Glossary
  • About
  • Login
Search Logo
Content Type
Topic
Unit

Can't find what you're looking for? You may need to login to see more documents.

Guidance
Dec 6, 2016

Evaluation, Screening and Diagnostic Testing for Determination of Clinical Trial Eligibility

Many investigators have expressed uncertainty concerning when consent should be obtained from a subject who is being evaluated for possible eligibility to participate in one or more clinical trials. The following guidance has been developed to...
Guidance
Aug 14, 2015

External Adverse Event (AE) Reporting

This page explains the required reporting for 'external' AEs. These are events that are under the direct oversight of non -UM investigators and non -UM IRBs , events about which the UM investigator receives a report, usually from the study sponsor...
Guidance
Jun 7, 2021

Other Reportable Information or Occurrence (ORIO)

Investigators sometimes receive information that has a direct impact on a research study. This information is reportable to the IRBMED . Frequently this information falls within the Adverse Event Reporting context, or it is reported to IRBMED in...
Guidance
Nov 28, 2022

Updating IRB applications when Researcher(s) Leave U-M

When a researcher (aka study team member) listed in an active (not Terminated or Withdrawn in eResearch) IRB application is leaving the University of Michigan, follow this guidance to update the corresponding IRB applications. Notify IRBMED early in...
Tags: Regulatory Principal Investigator
Guidance
Dec 18, 2020

Investigational In Vitro Diagnostics (IVDs) utilized in Clinical Investigations of Therapeutic Products

Human subjects research applications received by IRBMED include clinical investigations of therapeutic products that propose to utilize in vitro diagnostic (IVD) tests or assays. PDF version
Guidance
Sep 13, 2021

Protocol Resources

The study protocol should comprise all the key information about study conduct, including but not limited to rationale and scientific background, plans for subject interaction/intervention from recruitment through long-term follow-up, how the study...
Tags: Protocol Regulatory Study Coordinator Study Teams U-M resource
Guidance
Aug 22, 2022

Emergency Use of a Test Article in Life-Threatening Circumstances

This guidance describes the circumstances regarding Emergency Use of an investigational product (drug, biologic, or device) and the procedures to be followed before or immediately following the emergency use of an investigational product. Emergency...
Tags: Regulatory MICHR Investigator Initiated
Guidance
Jul 23, 2021

Multi-Site and Performance Site applications: Reporting to IRBMED

This document provides the reporting requirements to IRBMED for both Multi-Site HUM application and Performance Site HUM application when U-M is a coordinating center is not the single IRB (sIRB)/IRB of record/reviewing IRB for sites other than U-M...
Tags: Study Coordinator CTSO Work Guide
Policies
Dec 9, 2016

Recovering Full Indirect Costs: Industry Funded Research

This policy details the required process that should be used to negotiate the indirect cost rate with industry sponsors . The Medical School does not support indirect cost waivers on industry funded research. Please visit the Indirect Cost Waiver...
Guidance
Aug 10, 2020

Uses & Disclosures of Protected Health Information (PHI)

Protected Health Information (PHI) is individually identifiable health information held or maintained by covered entities , or by business associates acting for the covered entity. PHI is subject to HIPAA Privacy Rule protections. HIPAA Privacy Rule...
Policies
Apr 21, 2017

Indirect Cost Waiver

This policy addresses requests for reduced overhead recovery through the Indirect Cost Waiver mechanism.
Policies
Mar 23, 2018

Indirect Cost Recovery

The Medical School's expectations regarding the recovery of indirect costs from Federal, Industry/For-Profit, and Non-Profit sponsor s.
Guidance
Apr 10, 2018

Clinical Research Billing Guidance (CRB)

The Clinical Research Billing (CRB) process insures that services provided as part of a clinical study are billed properly to the sponsor or third-party payor. Many organizations (on campus and off) are involved, and compliance is required at...

Office of Research
University of Michigan Medical School
1301 Catherine Street SPC 5624
Ann Arbor, MI 48109

North Campus Research Complex (NCRC)
2800 Plymouth Road Building 520, 3rd Floor
Ann Arbor, MI 48109-2800

Phone: 734-615-1332
Fax: 734-615-9458
Email: ummsresearch@umich.edu

US News Best Grad Schools 2018
University of Michigan
Michigan Medicine
U-M Medical School Learn more about U-M compliance »
© 2023The Regents of the University of Michigan -- U-M Gateway Non-Discrimination Policy -- Michigan Web Design by Boxcar Studio